- Home
- XFOR vs IDR Comparison
XFOR vs IDR Comparison
Compare XFOR & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | IDR |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 378.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XFOR | IDR |
|---|---|---|
| Price | $3.98 | $39.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $28.50 | $17.50 |
| AVG Volume (30 Days) | ★ 879.6K | 676.6K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.70 |
| EPS | N/A | ★ 0.73 |
| Revenue | $33,979,000.00 | ★ $35,424,313.00 |
| Revenue This Year | $1,276.65 | $55.62 |
| Revenue Next Year | N/A | $23.93 |
| P/E Ratio | ★ N/A | $55.52 |
| Revenue Growth | ★ 2925.74 | 61.35 |
| 52 Week Low | $1.35 | $9.90 |
| 52 Week High | $26.83 | $54.70 |
Technical Indicators
Market Signals| Indicator | XFOR | IDR |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 47.18 |
| Support Level | $3.50 | $41.65 |
| Resistance Level | $4.56 | $48.75 |
| Average True Range (ATR) | 0.30 | 3.46 |
| MACD | 0.03 | -0.57 |
| Stochastic Oscillator | 47.91 | 9.29 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.